Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia

Huang,Xiao; Li,Dongyun; Li,Tiantian; Zhao,Bo; Chen,Xinyi

doi:10.3892/ol.2015.3189

Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia

Authors:
- Xiao Huang
- Dongyun Li
- Tiantian Li
- Bo Zhao
- Xinyi Chen
View Affiliations

Affiliations: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P.R. China, Department of Biostatistics, The University of Texas, Houston Health Science Center, Houston, TX 77030, USA
Published online on: May 6, 2015 https://doi.org/10.3892/ol.2015.3189
Pages: 103-110
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The leukemic stem cell marker CD44, has been reported to have prognostic significance in hematological malignancies. The present study therefore aimed to evaluate whether the expression levels of CD44 and the associated pathway components are associated with the survival rate of elderly patients with refractory acute myeloid leukemia (AML). A total of 20 elderly patients diagnosed with refractory AML were divided into two groups, following induction chemotherapy: Complete remission (CR, n=9) and non‑remission (NR. n=11). Bone marrow biopsy specimens were collected, expression levels of CD44, phosphatase and tensin homolog (PTEN), mammalian target of rapamycin (mTOR) and nuclear factor-κB (NF‑κB) were analyzed by immunohistochemistry and the captured images were analyzed in a blinded manner using Image Pro Plus software, version 6.0. The overall survival rates (OS) of the patients were then analyzed with log rank, and the correlation between CD44, PTEN, mTOR and NF‑κB expression levels and patients survival rates were statistically analyzed using Pearson's method. Significant differences were observed between the CR and NR groups for PTEN (P=0.025) and CD44 (P=0.020) expression levels. Positive CD44 expression was significantly correlated with poor overall survival, with a hazard ratio of 6.281 (95% CI, 1.78‑22.12; P=0.0042). The mean OS was 4.00 months for patients that demonstrated positive CD44 expression, compared with 9.27 months for patients that demonstrated negative CD44 expression. A tendency towards reduced survival rates was also observed in patients negative for PTEN expression, when compared with that of PTEN-positive patients. The mean OS was 4.81 months in PTEN-negative patients vs. 8.8 months in PTEN-positive patients, with a hazard ratio of 2.689 (95%CI, 0.89‑8.08; P=0.078). Patients that exhibited PTEN-positive and CD44-negative expression, survived significantly longer than patients that demonstrated PTEN-negative and CD44-positive expression (mean OS, 9.86 vs 2.67 months; hazard ratio=0.037; 95% CI, 0.006‑0.222, P=0.0006). The expression levels of NF‑κB and mTOR were slightly increased in the NR group compared with those of the CR group, although no significant differences were identified. PTEN and CD44 expression levels demonstrated trends towards negative correlation. In conclusion, the expression levels of CD44 and PTEN may be useful markers to predict the prognosis of elderly patients with refractory AML.

View Figures

View References

1	Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar : PubMed/NCBI
2	Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia A report of the French-American-British Cooperative Group. Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar : PubMed/NCBI
3	Bennett JM, Catovsky D, Daniel MT, et al: Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 103:460–462. 1985. View Article : Google Scholar : PubMed/NCBI
4	Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 78:325–329. 1991. View Article : Google Scholar : PubMed/NCBI
5	Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J. 1:53–66. 2000. View Article : Google Scholar : PubMed/NCBI
6	Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yates JW, Wallace HJ Jr, Ellison RR and Holland JF: Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 57:485–488. 1973.PubMed/NCBI
8	Rai KR, Holland JF, Glidewell OJ, et al: Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. Blood. 58:1203–1212. 1981.PubMed/NCBI
9	O'Donnell MR, Abboud CN, Altman J, et al: Acute myeloid leukemia. J Natl Compr Canc Netw. 10:984–1021. 2012.PubMed/NCBI
10	Swords R and Santini V: In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy? Hematology Am Soc Hematol Educ Program. 2012:74–75. 2012.PubMed/NCBI
11	Yanada M and Naoe T: Acute myeloid leukemia in older adults. Int J Hematol. 96:186–193. 2012. View Article : Google Scholar : PubMed/NCBI
12	Burnett A, Wetzler M and Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
13	Dombret H, Raffoux E and Gardin C: Acute myeloid leukemia in the elderly. Semin Oncol. 35:430–438. 2008. View Article : Google Scholar : PubMed/NCBI
14	Krug U, Büchner T, Berdel WE and Müller-Tidow C: The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int. 108:863–870. 2011.PubMed/NCBI
15	Jordan CT: The leukemic stem cell. Best Pract Res Clin Haematol. 20:13–18. 2007. View Article : Google Scholar : PubMed/NCBI
16	She M, Niu X, Chen X, et al: Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett. 318:173–179. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ardekani AM, Akhondi MM and Sadeghi MR: Application of genomic and proteomic technologies to early detection of cancer. Arch Iran Med. 11:427–434. 2008.PubMed/NCBI
18	Biomarkers Definitions Working Group, . Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 69:89–95. 2001. View Article : Google Scholar : PubMed/NCBI
19	Eisterer W, Bechter O, Hilbe W, et al: CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. Leuk Res. 25:1051–1057. 2001. View Article : Google Scholar : PubMed/NCBI
20	Niitsu N and Iijima K: High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leuk Res. 26:241–248. 2002. View Article : Google Scholar : PubMed/NCBI
21	Krause DS, Spitzer TR and Stowell CP: The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin's lymphoma. Arch Pathol Lab Med. 134:1033–1038. 2010.PubMed/NCBI
22	Mi Y and Bian S: Acute leukemiaStandardization of Hematologic Disease Diagnosis and the Therapeutic Effect. Zhinan Z and Ti S: 1. 3rd. Science Press; Beijing, China: pp. 131–134. 2007
23	Wang Z, Zheng T, Wu Q and Wang J, Wu C and Wang J: Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma. Neoplasma. 59:137–141. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hu J, Liu YL, Piao SL, et al: Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer. 77:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
25	Cao L, Hu X, Zhang J, Liang P and Zhang Y: CD44 U(+) CD324(–) expression and prognosis in gastric cancer patients. J Surg Oncol. 110:727–733. 2014. View Article : Google Scholar : PubMed/NCBI
26	Opitz I, Soltermann A, Abaecherli M, et al: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 33:502–506. 2008. View Article : Google Scholar : PubMed/NCBI
27	Tapia O, Riquelme I, Leal P, et al: The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
28	Sebban C, Browman GP, Lepage E and Fière D: Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: A prospective analysis of 437 cases and its application for designing induction chemotherapy trials. Leuk Res. 19:861–868. 1995. View Article : Google Scholar : PubMed/NCBI
29	Cortes J, Fayad L, O'Brien S, Keating M and Kantarjian H: Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res. 5:2491–2497. 1999.PubMed/NCBI
30	Fitzgerald KA, Bowie AG, Skeffington BS and O'Neill LA: Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells. J Immunol. 164:2053–2063. 2000. View Article : Google Scholar : PubMed/NCBI
31	Bourguignon LY, Zhu H, Shao L, Zhu D and Chen YW: Rho-kinase (ROK) promotes CD44v(3,8–10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton. 43:269–287. 1999. View Article : Google Scholar : PubMed/NCBI
32	Lin YH and Yang-Yen HF: The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 276:46024–46030. 2001. View Article : Google Scholar : PubMed/NCBI
33	Dick JE, Bhatia M, Gan O, Kapp U and Wang JC: Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells. 15:199–207. 1997. View Article : Google Scholar : PubMed/NCBI
34	Krause DS and Van Etten RA: Right on target: Eradicating leukemic stem cells. Trends Mol Med. 13:470–481. 2007. View Article : Google Scholar : PubMed/NCBI
35	Oelschlaegel U, Bornhauser M, Boxberger S, et al: Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol. 86:569–573. 2007. View Article : Google Scholar : PubMed/NCBI
36	van Rhenen A, Moshaver B, Kelder A, et al: Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 21:1700–1707. 2007. View Article : Google Scholar : PubMed/NCBI
37	Buzzai M and Licht JD: New molecular concepts and targets in acute myeloid leukemia. Curr Opin Hematol. 15:82–87. 2008. View Article : Google Scholar : PubMed/NCBI
38	Spaeth EL, Labaff AM, Toole BP, et al: Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res. 73:5347–5359. 2013. View Article : Google Scholar : PubMed/NCBI
39	Lane SW, Scadden DT and Gilliland DG: The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood. 114:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
40	Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
41	Stiles B, Groszer M, Wang S, Jiao J and Wu H: PTENless means more. Dev Biol. 273:175–184. 2004. View Article : Google Scholar : PubMed/NCBI
42	Dahia PL, Aguiar RC, Alberta J, et al: PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet. 8:185–193. 1999. View Article : Google Scholar : PubMed/NCBI
43	Cheong JW, Eom JI, Maeng HY, et al: Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol. 122:454–456. 2003. View Article : Google Scholar : PubMed/NCBI
44	Squarize CH, Castilho RM, Abrahao AC, et al: PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 15:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
45	da Costa AA, D'Almeida Costa F, Ribeiro AR, et al: Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab. Int J Clin Oncol. May 27–2014.(Epub ahead of print).
46	Hede K: PTEN takes center stage in cancer stem cell research, works as tumor suppressor. J Natl Cancer Inst. 98:808–809. 2006. View Article : Google Scholar : PubMed/NCBI
47	He XC, Yin T, Grindley JC, et al: PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet. 39:189–198. 2007. View Article : Google Scholar : PubMed/NCBI
48	Yilmaz OH, Valdez R, Theisen BK, et al: Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 441:475–482. 2006. View Article : Google Scholar : PubMed/NCBI
49	Tesio M, Oser GM, Baccelli I, et al: Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization. J Exp Med. 210:2337–2349. 2013. View Article : Google Scholar : PubMed/NCBI
50	Chu TH, Chan HH, Kuo HM, et al: Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget. 5:1475–1490. 2014.PubMed/NCBI
51	Salminen A and Kaarniranta K: Insulin/IGF-1 paradox of aging: Regulation via AKT/IKK/NF-kappaB signaling. Cell Signal. 22:573–577. 2010. View Article : Google Scholar : PubMed/NCBI
52	Dubrovska A, Kim S, Salamone RJ, et al: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. In: Proc Natl Acad Sci USA. 106. pp. 268–273. 2009; View Article : Google Scholar : PubMed/NCBI
53	Kim HJ, Hawke N and Baldwin AS: NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
54	Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 29:19–35. 2007. View Article : Google Scholar : PubMed/NCBI
55	Breccia M and Alimena G: NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets. 14:1157–1176. 2010. View Article : Google Scholar : PubMed/NCBI
56	Kamieńska E, Ociepa T, Wysocki M, et al: Activation of NF-κB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: Relation to other prognostic factors. Pol J Pathol. 62:5–11. 2011.PubMed/NCBI
57	Lounnas N, Frelin C, Gonthier N, et al: NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. Int J Cancer. 125:308–317. 2009. View Article : Google Scholar : PubMed/NCBI